The utility of prenatal ultrasonography for the detection of congenital masses

Abstract

Objective: Congenital masses are associated with an increased risk for perinatal complications and death; therefore prenatal imagining studies are fundamental to determine the optimal postnatal interventions. Herein we evaluate the usefulness of the prenatal ultrasonography in determination of congenital masses. Method: Nineteen newborn babies with mass were enrolled in this retrospective study. Data of the ultrasonographic diagnosis, gestational age at diagnosis, survival, and histological confirmation of the disease were reviewed. Results: Of the 19 newborn babies 8 male and 11 female with mass, 13 patients were diagnosed prenatally 68% . The location of the masses were abdominal n: 12 , thoracic n: 6 and cranial n: 1 . The ratio of prenatal diagnosis of abdominal, and thoracic mass was established as 10/12 83% , 3/6 50% , respectively. The intracranial mass could not be detected in the prenatal period. Definitive diagnosis of the prenatally detected masses were teratoma in 4 patients, ovary cystadenoma in 2 patients, Wilms tumor in 2 patients, neuroblastoma in 1 patient, and rhabdomyoma in 1 patient. The remaining 3 patients had variety of masses mesenteric cyst, gastroenteric cyst, lymphangioma . Conclusion: Our data shows that abdominal and cystic masses are more easily detected during prenatal periods by ultrasonographic examination.

Keywords

• Congenital mass, neonate, prenatal ultrasonography

Doğuştan kitlelerin tespiti için prenatal ultrasonografinin faydası

Abstract

Amaç: Konjenital kitleler artmış perinatal komplikasyon ve ölüm riski ile ilişkilidir. Bu nedenle doğum öncesi görüntüleme çalışmaları, optimum doğum sonrası müdahaleleri belirlemek için esastır. Biz bu yazıda; konjenital kitlelerin belirlenmesinde prenatal ultrasonografinin yararlılığını değerlendirdik. Yöntem: Kitlesi olan 19 yenidoğan bebek bu retrospektif çalışmaya alındı. Ultrasonografik tanı, tanı anındaki gebelik yaşı, hayatta kalma ve hastalığın histolojik doğrulama verileri incelendi. Bulgular: Kitlesi olan bu 19 yenidoğan bebeğin 8 erkek ve 11 kız , 13’ünde %68 tanı prenatal dönemde konuldu. Kitleler abdominal n: 12 , göğüs n: 6 ve kranial n: 1 yerleşimli idi. Abdominal ve torakal kitlelerin prenatal tanı oranları sırasıyla, 10/12 %83 , 3/6 %50 idi. Intrakranial kitle ise prenatal dönemde tespit edilemedi. Prenatal saptanan kitlelerin kesin tanıları, 4 hastada; teratom, 2 hastada; over kistadenomu, 2 hastada; Wilms tümörü, 1 hastada; nöroblastom ve 1 hastada da; rabdomiyom idi. Kalan 3 hastada ise çeşitli mezenter kisti, gastroenterik kist, lenfanjioma kitleler vardı. Sonuç: Bizim veriler abdominal ve kistik kitlelerin prenatal dönemde ultrasonografik inceleme ile daha kolay tespit edildiğini göstermektedir.

Keywords

• Konjenital kitle, prenatal ultrasonografi, yenidoğan.

References

1. 1. WHO 2010. Global Tuberculosis Control 2010. Available at http://www. whqlibdoc. who. int/publications/2010/9789241564069_eng.
2. 2. Dye C, Scheele S, Dolin P, Pathania V , Raviglione MC. Consensus statement. Global burden of tuberculosis:estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677–686.
3. 3. Paige C, Bishai WR. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe’s point of view. Cell Microbiol 2010; 12: 301-309.
4. 4. Barry CE III, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7: 845 - 855.
5. 5. T.C. Sağlık Bakanlığı Verem Savaş Daire Başkanlığı. Türkiye’de Tüberkülozun Kontrolü için Başvuru Kitabı. 2003;55-57.
6. 6. The Mantoux test, Administration, reading and interpretation 2006. Available at http://www.immunisation.ie/en/Downloads/PDFFil e_14983_en.pdf
7. 7. Lyng P. The Mantoux Test 2008. Available at http: //web.up.ac.za/sitefiles/file/45/1335/877/Mantoux Flipchart.pdf
8. 8. Thompson NJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587-97.

9. 9. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-7.
10. 10. Harboe M. Antigens of PPD, old tuberculin and autoclaved Mycobacterium bovis BCG studies by crossed immunoelectrophoresis. Am Rev Respir Dis 1981; 124: 80-7.
11. 11. Borsuk S, Newcombe J, Mendum TA, Dellagostin OA & McFadden J. Identification of proteins from tuberculin purified protein derivative (PPD) by LCMS/MS. Tuberculosis (Edinb) 2009; 89: 423–430.
12. 12. Shingadia D, Novelli V. The tuberculin skin test: a hundred, not out? Arch Dis Child 2008; 93: 189– 190.
13. 13. Snider DE Jr. Bacille Calmette-Guerin vaccination and tuberculin skin tests. JAMA 1985; 253: 3438-9.
14. 14. Centers for Disease Control. Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis. MMWR Morbid Mortal Wkly Rep 1988; 37: 663-75.
15. 15. A Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: 221-247.